Restricted accessResearch articleFirst published online 2017-7
Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome
Background: Teduglutide, a glucagon-like peptide-2 (GLP-2) analogue, is available for long-term use by parenteral nutrition (PN)–dependent adults to promote intestinal adaptation but is not approved for use in pediatric patients. The objective of this study was to assess teduglutide-stimulated induced intestinal adaptation, potential synergies with partial enteral nutrition (PEN), and distinct temporal markers of adaptation in a neonatal piglet model of short bowel syndrome (SBS). Materials and Methods: Neonatal piglets (48 hours old; n = 72) underwent an 80% jejunoileal resection and were randomized to 1 of 4 treatment groups, in a 2 × 2 factorial design, with PN or PEN (80% standard PN/20% standard enteral nutrition) and teduglutide (0.1 mg/kg/d) or control. Piglets received nutrient infusions for 4 hours, 48 hours, or 7 days. Results: Teduglutide improved (P < .05) mucosal surface area (villus height: duodenum, jejunum, ileum; crypt depth: ileum, colon; proliferation: duodenum, jejunum, ileum; colon; apoptosis: jejunum, ileum, colon) and acute nutrient processing capacity (glucose: duodenum, jejunum, ileum; glutamine: duodenum, jejunum). These effects were complemented and synergistically enhanced by PEN in both site and timing of action. Structural adaptations preceded functional adaptations, but crypt depth remained a strong indicator of adaptation, regardless of time. Conclusions: The combination of teduglutide and PEN enhances intestinal adaptation beyond that of either therapy alone.
WalesPChristison-LagayE. Short bowel syndrome: epidemiology and etiology. Semin Pediatr Surg. 2010;19:3-9.
2.
BatraABeattieRM. Management of short bowel syndrome in infancy. Early Hum Dev. 2013;89:899-904.
3.
WalesPde SilvaNKimJLecceLToTMooreA. Neonatal short bowel syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg. 2004;39:690-695.
4.
SchwartzM. Novel therapies for the management of short bowel syndrome in children. Pediatr Surg Int. 2013;29:967-974.
5.
MartinJHamiltonBOstermanMCurtinSMathewsT. Births: final data for 2013. Natl Vital Stat Rep. 2015;64(1):1-65.
6.
GouletOOliemanJKsiazykJ. Neonatal short bowel syndrome as a model of intestinal failure: physiological background for enteral feeding. Clin Nutr. 2013;32(2):162-171.
7.
KoletzkoBGouletOHuntJKrohnKShamirR. Guidelines on paediatric parenteral nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr. 2005;41(suppl 2):1-87.
8.
InoueYEspatNFrohnappleDEpsteinHCopelandESoubaW. Effect of total parenteral nutrition on amino acid and glucose transport by the human small intestine. Ann Surg. 1993;217:604-614.
9.
RossiTLeePYoungCTjotaA. Small intestinal mucosa changes, including epithelial cell proliferative activity, of children receiving total parenteral nutrition (PN). Dig Dis Sci. 1993;38:1608-1613.
10.
DuroDMitchellPKalishL. Risk factors for PN associated liver disease following surgical therapy for necrotizing enterocolitis: a Glaser Pediatric Research Network study. J Pediatr Gastroenterol Nutr. 2011;52(5):595-600.
11.
VargasJ. Short bowel syndrome/intestinal failure. J Pediatr. 2013;163(5):1243-1246.
12.
RoyCGroleauVBouthillierLPineaultMThibaultMMarchandV. Short bowel syndrome in infants: the critical role of luminal nutrients in a management program. Appl Physiol Nutr Metab. 2014;39:745-753.
BarnesJHartmannBHolstJTappendenK. Intestinal adaptation is stimulated by partial enteral nutrition supplemented with the prebiotic short-chain fructooligosacharide in a neonatal intestinal failure piglet model. JPEN J Parenter Enteral Nutr. 2012;36:524-537.
15.
DodgeMBertoloRBruntonJ. Enteral feeding induces profound early intestinal adaptation in a neonatal piglet model of short bowel syndrome. JPEN J Parenter Enteral Nutr. 2012;36(2):205-212.
16.
FeldmanEJDowlingRHMcNaughtonJPetersTJ. Effects of oral versus intravenous nutrition on intestinal adaptation after small bowel resection in the dog. Gastroenterology. 1976;70:712-719.
17.
GouletOOliemanJKsiazykJ. Neonatal short bowel syndrome as a model of intestinal failure: physiological background for enteral feeding. Clin Nutr. 2013;32:162-171.
18.
ColeCKocoshisS. Nutrition management of infants with surgical short bowel syndrome and intestinal failure. Nutr Clin Pract. 2013;28(4):421-428.
19.
BurrinDGStollBJiangR. Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: how much is enough?Am J Clin Nutr. 2000;71:1603-1610.
20.
TappendenKA. Mechanisms of enteral nutrient-enhanced intestinal adaptation. Gastroenterology. 2006;130:S93-S99.
21.
AminHHolstJHartmannBWallaceLWrightJSigaletD. Functional ontogeny of the proglucagon derived peptide axis in human neonates. Pediatrics. 2008;121:180-186.
22.
LovshinJYustaBIliopoulosI. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Endocrinology. 2000;141:4194-4201.
23.
YoshikawaHMiyataIEtoY. Serum glucagon-like peptide-2 levels in neonates: comparison between extremely low-birthweight infants and normal-term infants. Pediatr Int. 2006;48:464-469.
24.
SigaletDMartinMeddingsJHartmanBHolstJ. GLP-2 levels in infants with intestinal dysfunction. Pediatr Res. 2004;56:371-376.
25.
LitvakDHellmichMEversBBankerNTownsendC. Glucagon-like peptide-2 is a potent growth factor for small intestine and colon. J Gastrointest Surg. 1998;2(2):146-150.
26.
TsaiCHillMAsaSBrubakerPDruckerD. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol. 1997;273(1):E77-E84.
27.
BurrinDStollBGuanXCuiLChangXHolstJ. Glucagon-like peptide-2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005;146(1):22-32.
28.
BrubakerPIzzoAHillMDruckerD. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol. 1997;272(6):E1050-E1058.
29.
IvoryCWallaceLMcCaffertyDSigaletD. Interleukin-10–independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1202-G1210.
30.
SigaletDWallaceLHolstJMartinGKajiTTanakaH. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol. 2007;293:G211-G221.
31.
MoranGO’NeilCMcLaughlinJ. GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrier. Regul Peptides. 2012;178:95-101.
BremholmLHornumMAndersenUHartmannBHolstJJeppesenP. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept. 2011;168:32-38.
34.
HoyerupPHellstromPSchmidtP. Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patients. Regul Peptides. 2013;180:12-16.
35.
VeggeAThymannTLundP. Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates. Am J Physiol Gastrointest Liver Physiol. 2013;305:G277-G285.
36.
SigaletDde HeuvelEWallaceL. Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regul Peptides. 2014;88:70-80.
37.
SuriMTurnerJSigaletD. Exogenous glucagon-like peptide-2 improves outcomes of intestinal adaptation in a distal-intestinal resection neonatal piglet model of short bowel syndrome. Pediatr Res. 2014;76(4):370-377.
38.
LiuXNelsonDHolstJNeyD. Synergistic effect of supplemental enteral nutrients and exogenous glucagon-like peptide 2 on intestinal adaptation in a rat model of short bowel syndrome. Am J Clin Nutr. 2006;84:1142-1150.
39.
BrinkmanAMuraliSHittSSolversonPHolstJNeyD. Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure. Am J Physiol Gastrointest Liver Physiol. 2012;303:G610-G622.
40.
MarierJBeliveauMMouksassiM. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008;48:1289-1299.
41.
MarierJMouksassiMGosselinNBeliveauMCyranJWallensJ. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn’s disease. J Clin Pharmacol. 2010;50:36-49.
ThymannTStollBMecklenburgL. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in newborn pigs with short bowel syndrome. J Pediatr Gastroenterol Nutr. 2014;58(6):694-702.
44.
MoughanPBirtlesMCranwellPSmithWPedrazaM. The piglet as a model animal for studying aspects of digestion and absorption in milk-fed human infants. World Rev Nutr Diet. 1992;67:40-113.
45.
WykesLBallRPencharzP. Development and validation of a total parenteral nutrition model in the neonatal piglet. J Nutr. 1993;123(7):1248-1259.
46.
TurnerJWalesPNationPN. Novel neonatal piglet models of surgical short bowel syndrome with intestinal failure. J Pediatr Gastroenterol Nutr. 2011;52(1):9-16.
47.
BartholomeAAlbimDBakerDHolstJTappendenK. Supplementation of total parenteral nutrition with butyrate acutely increases structural aspects of intestinal adaptation after an 80% jejunoileal resection in neonatal piglets. JPEN J Parenter Enteral Nutr. 2004;28(4):210-223.
48.
National Research Council. Nutrition Requirements of Swine. Washington, DC: National Academies Press; 1999.
49.
LattSStettenG. Spectral studies on 33258 Hoechst and related bisbenzimidazole dyes useful for fluorescent detection of deoxyribonucleic acid synthesis. J Histochem Cytochem. 1976;24(1):24-33.
50.
BradfordM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;7(72):248-254.
51.
JolliffeI. Principal Component Analysis. New York, NY: Springer; 2002.
ColombVDarcy-VrillonBJobertA. Parenteral nutrition modifies glucose and glutamine metabolism in rat isolated enterocytes. Gastroenterology. 1997;112(2):429-436.
55.
HowardAGoodladRWaltersJFordDHirstB. Increased expression of specific intestinal amino acid and peptide transporter mRNA in rats fed by PN is reversed by GLP-2. J Nutr. 2004;134(11):2957-2964.
56.
KatoYYuDSchwartzM. Glucagon-like peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg. 1999;34(1):18-21.
57.
ParkYMonacoMDonovanS. Enteral insulin-like growth factor-I augments intestinal disaccharidase activity in piglets receiving total parenteral nutrition. J Pediatr Gastroenterol Nutr. 1999;29(2):198-206.
58.
PrasadRAlaviKSchwartzM. Glucagon-like peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg. 2000;35(2):357-359.
59.
StollBPricePReedsP. Feeding an elemental diet vs a milk-based formula does not decrease intestinal mucosal growth in infant pigs. JPEN J Parenter Enteral Nutr. 2006;30(1):32-39.
60.
MouksassiMMarierJCyranJVinksA. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther. 2009;86(6):667-671.
61.
SeidnerDJolyFYoussefN. Effect of teduglutide, a glucagon-like peptide 2 analog, on citrulline levels in patients with short bowel syndrome in two phase III randomized trials. Clin Transl Gastroenterol. 2015;25(6):e93.
62.
ChaturvediLBassonM. Glucagon-like peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells. JAMA Surg. 2013;148(11):1037-1042.
63.
Ruiz-GrandeCPintadoJAlarcónCCastillaCValverdeILópez-NovoaJ. Renal catabolism of human glucagon-like peptides 1 and 2. Can J Physiol Pharmacol. 1990;68:1568-1573.
64.
JeppesenPGilroyRPertkiewiczMAllardJPMessingBO’KeefeSJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902-914.
65.
CompherCGilroyRPertkiewiczM. Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2011;35(5):603-609.
66.
OhlhorstSRussellRBierD. Nutrition research to affect food and a healthy life span. Am J Clin Nutr. 2013;98:620-625.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
